Probiotic Bacterial Compositions for Cystic Fibrosis Microbiome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis, particularly enzyme replacement therapy, do not effectively establish a healthy intestinal microbiota in patients, leading to ongoing gastrointestinal complications and increased risk of pulmonary exacerbations.
Innovation Solution
Administration of bacterial compositions containing Bifidobacterium, Bacteroides, Streptococcus, and Ruminococcus to alter the intestinal microbiota, thereby modifying the gut microbiome to improve systemic health and reduce the risk of cystic fibrosis-associated clinical outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy is used to treat cystic fibrosis, then pancreatic insufficiency is improved, but intestinal microbiota remains altered and gastrointestinal complications persist
Solution Approach 1:
The patent introduces bacterial compositions (probiotics) as an intermediary agent to mediate between the host and the altered microbiota. These compositions contain specific bacteria that act as mediators to restore healthy microbial balance in the intestine, addressing the harmful effects of enzyme replacement therapy while maintaining its beneficial pancreatic function support.
Solution Approach 2:
The patent extracts and isolates specific beneficial bacterial strains from healthy microbiota sources. By taking out these specific beneficial bacteria and concentrating them in formulated compositions, the invention creates targeted probiotic treatments that can specifically address the microbiota alterations caused by enzyme replacement therapy without introducing unnecessary components.
2Object-affected harmful factors
If traditional CF treatments are used, then airway infections are addressed, but gastrointestinal complications and pulmonary exacerbation risk increase
Solution Approach 1:
The patent segments the treatment approach by separating the management of airway infections from gastrointestinal health. While traditional treatments address airway infections, this invention introduces a distinct probiotic intervention specifically targeted at restoring intestinal microbiota balance, thereby addressing gastrointestinal complications without interfering with airway infection management.
Solution Approach 2:
The patent applies preliminary action by introducing beneficial bacteria to restore healthy microbiota before gastrointestinal complications fully develop. By proactively establishing a healthy microbial balance in the intestine, the treatment prevents the development of gastrointestinal complications and reduces the risk of pulmonary exacerbations before they occur.
3Reliability
If bacterial compositions are administered to alter intestinal microbiota, then pulmonary exacerbation risk is reduced, but treatment complexity increases
Solution Approach 1:
The patent applies universality by creating a multi-functional probiotic treatment that simultaneously addresses multiple health outcomes. The bacterial compositions not only restore intestinal microbiota balance but also reduce pulmonary exacerbation risk, improve gastrointestinal health, and potentially enhance overall disease outcomes, thereby providing multiple benefits through a single intervention.
Solution Approach 2:
The patent utilizes parameter changes by modifying the microbiota composition parameters in the intestine. By introducing specific bacterial strains that change the microbial community structure, the treatment achieves systemic effects including reduced pulmonary exacerbation risk. The compositions are designed with optimized parameters such as bacterial strain selection, ratios, and delivery formulations to maximize efficacy while minimizing complexity.
Data Source
AI summary
The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.